摘要
目的:总结小儿支原体肺炎治疗中阿奇霉素、孟鲁司特钠联合用药方案的临床价值。方法:选取2022年5月—2024年3月在广州市花都区妇幼保健院儿科收治的100名肺炎支原体肺炎患儿作为研究对象,采用随机数表法将其分为对照组和研究组,每组各50例。对照组仅使用阿奇霉素进行治疗,而研究组在对照组的治疗方案上增加孟鲁司特钠联合治疗。比较两组治疗效果、肺功能[达峰时间比(t-PTEF/t-E)、潮气量(V-T)、吸气中期流速和呼气中期流速比值(MTIF/MTEF)、用力肺活量(FVC)、最大呼气峰流速(PEF)、第1秒用力呼气容积(FEV_(1))]、炎症因子指标[C反应蛋白(CRP)、降钙素原(PCT)、红细胞沉降率(ESR)]、症状(咳嗽、无憋喘、啰音消失、退热)消失时间、不良反应(头晕、恶心呕吐、腹痛腹泻)发生率。结果:研究组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组肺功能水平均有所提升,其中研究组的肺功能水平提升幅度高于对照组,两组炎症因子水平均较治疗前有所下降,研究组的下降幅度显著低于对照组,症状缓解时间短于对照组,不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:阿奇霉素联合孟鲁司特钠治疗儿童支原体肺炎的疗效确切,有助于提升患儿的肺功能,缓解炎症反应,加速临床症状的改善,具有较高的治疗安全性。
Objective:To investigate the effectiveness of azithromycin in conjunction with Montelukast sodium for treating mycoplasma pneumoniae pneumonia in children.Method:A total of 100 pediatric patients diagnosed with mycoplasma pneumoniae pneumonia,who were treated in the hospital from May 2022 to March 2024 were chosen as study subjects.These patients were randomly divided into two groups,with 50 patients in each group.The control group received azithromycin alone,whereas the study group was given a combination of azithromycin and Montelukast sodium.The outcomes measured included treatment efficacy,lung function parameters[such as peak time ratio(t-PTEF/t-E),tidal volume(V-T),mid-inspiratory flow rate to mid-expiratory flow rate ratio(MTIF/MTEF),forced vital capacity(FVC),maximum peak expiratory flow rate(PEF),and forced expiratory volume in one second(FEV_(1))],inflammatory markers[C-reactive protein(CRP),procalcitonin(PCT),and erythrocyte sedimentation rate(ESR)],duration of symptom resolution(cough,wheezing,rales,and fever),and the occurrence of adverse effects(dizziness,nausea,vomiting,abdominal pain,and diarrhea)of two groups were compared.Result:The overall effectiveness in the study group was notably superior to that in the control group(P<0.05).After treatment,both groups showed improvements in lung function,but the study group exhibited better results(P<0.05).Both groups experienced a reduction in inflammatory marker levels compared to pre-treatment,but the study group had a more pronounced decrease(P<0.05).The study group also had a shorter symptom resolution time than the control group(P<0.05).Additionally,the incidence of adverse reactions was lower in the study group,with statistically significant difference(P<0.05).Conclusion:The combination of azithromycin and Montelukast sodium is effective in treating mycoplasma pneumonia in children,contributing to improving lung function,reducing inflammation,and accelarting clinical symptom improvement,with high therapeutic safety.
作者
胡志南
江锶婷
HU Zhinan;JIANG Siting(Huadu Maternal and Child Health Hospital,Guangzhou 510000,China;不详)
出处
《中外医学研究》
2025年第22期137-141,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
孟鲁司特钠
阿奇霉素
小儿肺炎支原体肺炎
临床效果
肺功能
Montelukast sodium
Azithromycin
Mycoplasma pneumonia in children
Clinical effect
Lung function
